Immunological problems; She gets sick twice; This spontaneous case was reported by a consumer and describes the occurrence of IMMUNODEFICIENCY (Immunological problems) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 prophylaxis. The occurrence of additional non-serious events is detailed below.    Co-suspect product included non-company product NIRMATRELVIR;RITONAVIR for an unknown indication.    No Medical History information was reported.   On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form On an unknown date, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form and third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. and NIRMATRELVIR;RITONAVIR (unknown route) at an unspecified dose. On an unknown date, the patient experienced IMMUNODEFICIENCY (Immunological problems) (seriousness criterion medically significant) and ILLNESS (She gets sick twice). At the time of the report, IMMUNODEFICIENCY (Immunological problems) and ILLNESS (She gets sick twice) outcome was unknown.            No concomitant medication was provided. Treatment medication was not provided by the reporter.  This case was identified as part of a retrospective clean-up activity where certain emails received in the Moderna mailbox were missed to be booked-in  Company comment  This spontaneous case reported by a consumer, concerns a female patient of unknown age, with no relevant medical history, who experienced the unexpected, serious (medically significant) event of Immunodeficiency (Immunological problems) unknown days after receiving the 3 dose of mRNA-1273 vaccine in the covid 19 vaccination series, along with the non serious event of Illness. It was reported that she got sick twice. Patient had previously received the 2 primary doses with Moderna vaccine with no adverse events reported. It was reported that the patient received NIRMATRELVIR;RITONAVIR at an unspecified dose for an unknown indication, which is a confounder for the event. No further clinical information on other comorbidities, risk factors, symptoms, labs, diagnostics, concomitant medications and treatment were reported. The benefit-risk relationship of mRNA- 1273 vaccine is not affected by this report.; Sender's Comments: This spontaneous case reported by a consumer, concerns a female patient of unknown age, with no relevant medical history, who experienced the unexpected, serious (medically significant) event of Immunodeficiency (Immunological problems) unknown days after receiving the 3 dose of mRNA-1273 vaccine in the covid 19 vaccination series, along with the non serious event of Illness. It was reported that she got sick twice. Patient had previously received the 2 primary doses with Moderna  vaccine with no adverse events reported. It was reported that the patient received  NIRMATRELVIR;RITONAVIR at an unspecified dose for an unknown indication, which is a confounder for the event. No further clinical information on other comorbidities, risk factors, symptoms, labs, diagnostics, concomitant medications and treatment were reported. The benefit-risk relationship of mRNA- 1273 vaccine is not affected by this report.